Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity

Basit Öğe Kaydı
dc.contributor.authorÖzdemir, Enver
dc.contributor.authorDokucu, Ali İhsan
dc.contributor.authorUzunlar, Ali Kemal
dc.contributor.authorEce, Aydın
dc.contributor.authorYaldız, Mehmet Sadık
dc.contributor.authorÖztürk, Hayrettin
dc.contributor.orcid0000-0001-6764-8336
dc.date.accessioned2024-04-24T17:56:12Z
dc.date.available2024-04-24T17:56:12Z
dc.date.issued2002
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalıen_US
dc.description.abstractPurpose: Cisplatin (CCDP), an indispensable agent of several chemotherapy protocols, has serious dose limiting side effects, including nephrotoxicity. In this experimental study, we used deferoxamine mesilate (DFO), an iron chelating agent, to ameliorate cisplatin-induced nephrotoxicity. Materials and methods: Sixty adult male bulb-c mice were divided in 6 equal groups. Group 1 received distilled water, group 2 received 100 mg/kg DFO, group 3 received 0.9 mg/kg CCDP, group 4 received 100 mg/kg DFO one hour before 0.9 mg/kg CCDP, group 5 received 1.8 mg/kg CCDP, and group 6 received 200 mg/kg DFO one hour before 1.8 mg/kg CCDP transperitoneally for 10 days. The next day, blood and urine samples were obtained, and all the animals were sacrificed, the kidneys and testes were removed, and histopathologic and biochemical analyses were performed. Results: Low-dose and high-dose CCDP treated mice had significantly more extensive proximal tubular degeneration (p < 0.001) when compared to control animals. Moreover, these changes were significantly less extensive in the mice taking DFO than mice taking CCDP. DFO showed no effect on cisplatin induced testicular histopathology. The cisplatin administration significantly increased the serum urea and plasma creatinin concentrations, and DFO administration prior to CCDP significantly decreased serum urea and plasma creatinin concentrations. Conclusion: Our findings suggest that DFO administration may be safe and useful for ameliorating cisplatin-induced nephrotoxicity.en_US
dc.identifier.citationÖzdemir, E., Dokucu, A. İ., Uzunlar, A. K., Ece, A., Yaldız, M. S. ve Öztürk, H. (2002). Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity. International Urology and Nephrology, 33(1), 127-131.
dc.identifier.doi10.1023/A:1014442027991
dc.identifier.endpage131en_US
dc.identifier.issn0301-1623
dc.identifier.issue1en_US
dc.identifier.pmid12090318
dc.identifier.scopus2-s2.0-0036050563
dc.identifier.scopusqualityQ2
dc.identifier.startpage127en_US
dc.identifier.urihttps://doi.org/10.1023/A:1014442027991
dc.identifier.urihttps://hdl.handle.net/11468/23370
dc.identifier.urihttps://link.springer.com/article/10.1023/A:1014442027991
dc.identifier.volume33en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAkademiai Kiado Rt.en_US
dc.relation.ispartofInternational Urology and Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBulb-C Miceen_US
dc.subjectCisplatinen_US
dc.subjectDeferoxamine mesilateen_US
dc.subjectNephrotoxicityen_US
dc.titleExperimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicityen_US
dc.titleExperimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity.pdf
Boyut:
110.6 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu